Kostial K, Kargacin B, Arezina R, Landeka M, Simonović I
Department of Mineral Metabolism, University of Zagreb, Yugoslavia.
J Hyg Epidemiol Microbiol Immunol. 1991;35(4):337-50.
The purpose of the present study was to obtain new data on the effect of age, route, dose and time of metal and chelating agent administration on the efficiency of chelation therapy. The experiments were performed on 1-2 and 6-week-old rats which received radioisotopes of metals--203Pb, 115 mCd, 203Hg and 141Ce intraperitoneally or orally. Chelating agents calcium ethylenediaminetetraacetate (CaEDTA), calcium and zinc diethylenetriaminepentaacetate (CaDTPA, ZnDTPA), 2,3-dimercapto-propane-sulfonate-1 (DMPS), dimercaptosuccinic acid (DMSA) and sodium N-(4-methoxybenzyl)-D-glucamine dithiocarbamate monohydrate (MeOBDCG) were administered twice by intraperitoneal or oral administration as early (immediately and 24 hr after metals) or delayed treatment (24 and 48 or 48 and 72 hr after metals). The animals were killed six days after metal administration and the retention was determined in the whole body, carcass and gut. After intraperitoneal administration of metals and chelating agents chelation therapy had much lower efficacy in younger than older animals. After ingestion of metals oral chelation therapy was more effective in younger than older animals. In suckling rats the treatment effectively reduced metal retention and this was mostly due to decrease in gut retention. This treatment in sucklings was also very effective in condition of late administration. In older rats early oral DMPS treatment after 203Hg ingestion is contraindicated since it increases significantly mercury retention while DMSA and ZnDTPA treatments reduced mercury retention. Delayed oral treatment with ZnDTPA and DMSA caused increased cadmium retention in older rats and decreased retention in sucklings. Opposite to results with CaDTPA, MeOBDCG was effective in reducing cadmium retention also when given as delayed treatment.(ABSTRACT TRUNCATED AT 250 WORDS)
本研究的目的是获取关于年龄、给药途径、金属及螯合剂剂量和给药时间对螯合疗法效果影响的新数据。实验在1 - 2周龄和6周龄的大鼠身上进行,这些大鼠通过腹腔注射或口服接受金属放射性同位素——203Pb、115mCd、203Hg和141Ce。螯合剂乙二胺四乙酸钙(CaEDTA)、二乙烯三胺五乙酸钙和锌(CaDTPA、ZnDTPA)、2,3 - 二巯基丙烷磺酸钠 - 1(DMPS)、二巯基丁二酸(DMSA)和N -(4 - 甲氧基苄基)- D - 葡糖胺二硫代氨基甲酸钠一水合物(MeOBDCG)通过腹腔注射或口服给药两次,作为早期(金属给药后立即和24小时)或延迟治疗(金属给药后24和48小时或48和72小时)。金属给药六天后处死动物,测定全身、 carcass和肠道中的潴留量。腹腔注射金属和螯合剂后,螯合疗法在年幼动物中的疗效远低于年长动物。摄入金属后,口服螯合疗法在年幼动物中比在年长动物中更有效。在乳鼠中,该治疗有效降低了金属潴留,这主要是由于肠道潴留减少。在延迟给药的情况下,这种治疗对乳鼠也非常有效。在年长大鼠中,摄入203Hg后早期口服DMPS治疗是禁忌的,因为它会显著增加汞潴留,而DMSA和ZnDTPA治疗可降低汞潴留。ZnDTPA和DMSA延迟口服治疗导致年长大鼠镉潴留增加,而乳鼠镉潴留减少。与CaDTPA的结果相反,MeOBDCG即使作为延迟治疗给药,也能有效降低镉潴留。(摘要截短至250字)